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Background: Announcements of interim analyses of a clinical trial convey information about the results beyond
the trial’s Data Safety Monitoring Board (DSMB). The amount of information conveyed may be minimal, but the fact
that none of the trial’s stopping boundaries has been crossed implies that the experimental therapy is neither
extremely effective nor hopeless. Predicting success of the ongoing trial is of interest to the trial’s sponsor, the
medical community, pharmaceutical companies, and investors. We determine the probability of trial success by
quantifying only the publicly available information from interim analyses of an ongoing trial. We illustrate our
method in the context of the National Surgical Adjuvant Breast and Bowel (NSABP) trial, C-08.
Methods: We simulated trials based on the specifics of the NSABP C-08 protocol that were publicly available. We
quantified the uncertainty around the treatment effect using prior weights for the various possibilities in light of other
colon cancer studies and other studies of the investigational agent, bevacizumab. We considered alternative
prior distributions.
Results: Subsequent to the trial’s third interim analysis, our predictive probabilities were: that the trial would eventually
be successful, 48.0%; would stop for futility, 7.4%; and would continue to completion without statistical significance,
44.5%. The actual trial continued to completion without statistical significance.
Conclusions: Announcements of interim analyses provide information outside the DSMB’s sphere of confidentiality. This
information is potentially helpful to clinical trial prognosticators. ‘Information leakage’ from standard interim analyses such
as in NSABP C-08 is conventionally viewed as acceptable even though it may be quite revealing. Whether leakage from
more aggressive types of adaptations is acceptable should be assessed at the design stage.
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Interim analyses of clinical trials convey information be-
yond the sphere of confidentiality of a trial’s Data and
Safety Monitoring Board (DSMB). A press release from
the sponsor may announce, ‘Good news! The DSMB rec-
ommends that the trial continue,’ or the opposite reac-
tion: ‘Shares of Oncothyreon dove over 40% on Tuesday
after the [announcement] that a phase III clinical trial
for Stimuvax [would] continue for several more months’
[1]. Such public announcements indicate that the results
have not crossed a stopping boundary. An implication is* Correspondence: don@berryconsultants.com
1Berry Consultants, LLC, 4301 Westbank Dr, Suite 140, Bldg B, Austin, TX
78746, USA
3University of Texas M.D. Anderson Cancer Center, P.O. Box 310402, Houston,
TX 77230, USA
Full list of author information is available at the end of the article
© 2014 Broglio et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.that the experimental therapy is neither extremely ef-
fective nor hopeless nor obviously unsafe. In the case of
Stimuvax, Wall Street had convinced itself that the prod-
uct was so good that crossing an early efficacy boundary
was a foregone conclusion [2].
Trial sponsors are obviously interested in the results
of interim analyses. Other interested parties include trial
investigators, patients, venture capitalists, stockbrokers,
and the sponsor’s competitors. When processing an-
nouncements of DSMB recommendations, and if left to
their own devices, people process information badly,
usually overestimating or underestimating. In the words
of Daniel Kahneman, ‘intuitive impressions of the diag-
nosticity of evidence are often exaggerated’ [3]. We illus-
trate a methodology for incorporating only the publicly
available results of interim decisions in order to find theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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that the interim analysis rules from the trial’s protocol
are available to the assessor.
Finding the probability of trial success based on interim
information requires the probability of success separate
from, or prior to, that information. The probability of trial
success based on the prior and currently available infor-
mation, and not assuming any particular hypothesis
about treatment effects is called ‘predictive power,’ and
contrasts with both traditional power and conditional
power. Traditional power, assessed at the design stage,
assumes a particular ‘clinically significant’ treatment ef-
fect [4]. Conditional power, assessed at an interim point
in the trial, conditions on the current data, and assumes
a particular point estimate (usually the maximum likeli-
hood estimate) for the treatment effect. Both traditional
power and conditional power may be considered across
a variety of scenarios, but the assumed treatment effect
in each scenario is fixed. By contrast, predictive power
is a weighted average of power over the current ‘poster-
ior’ distribution of the unknown treatment effects [5].
The distribution of treatment effects prior to observing
any information from the trial; that is, the prior distribu-
tion, depends on phase 2 results; evidence from trials in-
volving similar treatments, such as drugs in the same
class; and evidence from trials with the same treatment
but different diseases. It also depends on the person mak-
ing the assessment, which gives the Bayesian approach an
explicitly subjective flavor. One person may be pessimistic
about successfully developing a treatment for a particular
disease, whereas another may be optimistic. The hypothe-
sized effect used in powering a clinical trial tends to be op-
timistic; for example, it may be based on the results of
phase 2 trials. Such an estimate is biased and subject to
regression to the mean [6,7]. Evidence for this statement
is that phase 3 clinical trials have at least 80% power,
and yet no therapeutic area achieves a success rate even
approaching this level [8].
An honestly assessed prior distribution allocates some
probability to treatment effects that are less optimistic
than the one used in powering the trial. It might also as-
sign some probability to more optimistic treatment ef-
fects. Perhaps the prior distribution is symmetric about
its mean, and the mean is the effect at which the trial is
powered. The excess in power above the mean does not
begin to compensate for the loss in power below the
mean. Therefore, properly incorporating uncertainty, the
predictive calculations give a probability of success that
is less than the calculated power. An empirically based
rule of thumb is that trials built to have 80% power have
a success probability of 60%. Moreover, the mean of the
prior distribution is usually too optimistic. Discounting
for excessive optimism decreases predictive power still
more, to even less than 50%.We illustrate our methodology using the National Surgi-
cal Adjuvant Breast and Bowel Project trial C-08 (NSABP
C-08) [9]. This trial evaluated the benefit of adding bevaci-
zumab (Avastin®; Genentech/Roche) to modified infusional
fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) in
treating colon cancer.
Methods
NSABP C-08 study design
NSABP C-08 randomized patients with stage II or III
colon cancer equally to mFOLFOX6 (control group) ver-
sus bevacizumab plus mFOLFOX6 (experimental group).
The primary endpoint was disease-free survival (DFS)
measured from randomization to the first recurrence,
second primary cancer, or death from any cause. Based
on previous studies, the control event rate was expected
to be highest in the first 3 years. In total, 2,632 patients
were planned to give 90% power to detect an anticipated
25% reduction in the hazard of recurrence. The primary
analysis would be a one-sided log-rank test.
The trial’s target monthly accrual rate was expected to
increase from 63 to 105 patients over the first 2 years,
completing accrual within 30 months. The protocol-
defined final analysis was to occur at 592 DFS events.
The first interim analysis was planned after 148 DFS
events (25% information), approximately 2 years after
trial initiation. Subsequent analyses were planned every
6 months. Neither the number of analyses nor the sig-
nificance level of the final analysis were predetermined,
but would depend on alpha spending [10]. However, the
investigators anticipated six interim analyses, which is
what we assumed in our simulations. The stopping rule
used asymmetric boundaries for superiority and futility
indexed by one-sided P-values (Table 1). Maximal trial
duration was expected to be 5 years, including 2.5 years
of follow-up after the final patient was accrued.
Statistical simulations
We simulated trial results based on the publicly available
specifics of the NSABP C-08 design and the results of
previous interim analyses. We assumed particular treatment
effects (see below) to generate virtual patients based on the
assumed accrual rates, and followed their DFS events over
time. These virtual patients experienced DFS events over
time, depending on the assumed effect of their assigned
treatment. Each simulated trial stopped or not at interim
analyses, according to the boundary defined in Table 1. If it
did not stop early then we compared the log-rank P-value
to the final one-sided significance level of 0.0246, as shown
in Table 1. When a simulated trial stopped at an interim
analysis we recorded that fact and the result. For each
simulation, we recorded whether, when, and why the trial
stopped, and the eventual statistical conclusion. We iter-
ated this process 70,000 times for each assumption about
Table 1 National Surgical Adjuvant Breast and Bowel Project trial C-08 (NSABP C-08) interim monitoring bounds in
terms of one-sided P-values
Interim analysis Estimated time, years Stop for futility if
right-sided P-value <
Stop for superiority if
left-sided P-value <
Number of events Estimated accrual
at interim
1 2.0 0.05 0.00025 148 2,006
2 2.5 0.25 0.0005 ~220 2,632
3 3.0 0.5 0.001 ~312 2,632
4 3.5 0.5 0.001 ~398 2,632
5 4.0 0.5 0.001 ~473 2,632
6 4.5 0.5 0.001 ~538 2,632
Final 5.0 N/A ~0.0246 592 2,632
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outcomes of interest (such as that the trial continues at
the third interim analysis, but stops for superiority of the
experimental arm at the fourth interim analysis) are the
estimated probabilities of those outcomes.
We followed the assumption in the trial’s protocol
when generating the time that each virtual patient would
experience a DFS event. Specifically, we assumed a piece-
wise exponential distribution with control hazard rate
0.089 for the first 3 years, reducing to 0.039 in subsequent
years. When generating patients in the bevacizumab group,
we assumed a constant hazard ratio versus control.
The treatment effect was the reduction in hazard due to
bevacizumab. Any value from negative infinity to 100%
was possible, but the practical range was 0 to 40%. We
assigned (prior) weights to values in this range, in incre-
ments of 5%. Figure 1 gives example relative weights.
The ‘custom’ prior distribution in Figure 1 was that
assessed (by author DAB) during the NSABP C-08 trial.
This prior was not based on any knowledge of trial re-
sults, but considered publicly available information from
other colon cancer trials and from other trials of bevacizu-
mab [9,11-15]. The available information was consistent
with reductions of 10% and 15%, with little suggestion that
the reduction could be 30% or greater.
The other prior distributions shown in Figure 1 were
used to address the sensitivity of our conclusions to the
prior assessments. ‘Simple’ gave equal weight to each pos-
sible reduction; ’pessimistic’ concentrated weight on little
or no reduction; ‘moderate’ focused on 15% and 20% re-




Figure 2(A) shows the cumulative predictive probability
of success (bottom five lines) and the cumulative pre-
dictive probability of futility (top five lines). The steep
increase in the cumulative probability of success at the
final analysis reflects the larger P-value boundary used at
the end of the trial compared with those used for interimanalyses. Based on the custom prior distribution, the over-
all probability of statistical success was 47.5%, much less
than the trial’s advertised power of 90%. The predictive
probability of success is substantially lower than the power
because it incorporates uncertainty in the hazard reduc-
tion, and gives weight to hazard reductions of less than
25% (at which power was evaluated). The cumulative
probability of success by the final analysis based on the
‘optimistic’ prior was 76%, which was still less than the tri-
al’s planned power. This is despite the fact that this prior
distribution was centered close to the 25% reduction as-
sumed in the protocol. The decrement in the probability
of success is due to the uncertainty that is explicitly con-
sidered in the prior distribution.
The increases in the cumulative probability of futility
from the first and third interim analyses reflect the less
stringent futility stopping bounds subsequent to the sec-
ond interim analysis; futility is a possibility only at interim
analyses. Based on the custom prior, the overall probabil-
ity of futility was 20.4%. This ranged from 5.8% with the
optimistic prior, to 34.3% with the pessimistic prior. The
cumulative custom probability the trial would remain un-
decided at the final analysis was 32.1%. The cumulative
probability of ‘undecided’ ranged from 18% for the opti-
mistic prior, to 37.4% for the pessimistic prior.
Figure 2(B) shows the predictive probability of success
and the predictive probability of futility, conditional on
the previous interim analysis decision being to continue.
Figure 2(C) shows the predictive probabilities of even-
tual success and the predictive probabilities of eventual
futility. Figure 2(C) indicates that the probability of eventual
success in the trial, given that it continues, decreases only
slightly over time. In this sense, announcing the DSMB’s
recommendation to continue is not very informative.
Actual trial conduct
Figure 3 shows the timeline of NSABP C-08 and our
predictions. The trial began in September 2004 [9]. In
February 2006, accrual was temporarily halted to allow
the DSMB to review adverse event data. Accrual resumed
in May 2006. Accrual was faster than expected, and was
Figure 1 Prior distributions of the treatment benefits given in terms of relative strengths of belief in hazard reduction due to
bevacizumab. Abbreviations s, simple; p, pessimistic; o, optimistic; m, moderate; and c, custom.
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[9]. The first interim analysis was conducted in April 2007.
Our analysis of the predictive probability of the trial’s
success was conducted in June 2008, after the third in-
terim analysis. We made our software and ‘custom’ prior
distribution public on June 12, 2008 via a webinar spon-
sored by UBS Bank. Our predictive probabilities for the
fourth interim analysis were 9.8% for success and 3.8%
for futility. At that time, our predictive probabilities of
eventual success, stopping early for futility, and continu-
ing to completion without statistical significance were
48.0%, 7.4%, and 44.5%, respectively.
Our analysis depended on the assumed prior probabil-
ities, the roots of which are subjective [16]. An Excel
spreadsheet that carries out the calculations described in
this article is available at http://www.berryconsultants.com/
wp-content/uploads/2014/02/Unknown-Hazard-Reduction.
xls (Figure 4). It allows the user to input a prior distribution
by entering a weight for each of the indicated hazard reduc-
tions. The sum of the weights is arbitrary; only their relative
sizes matter. The weights convey confidence in the corre-
sponding hazard reductions, and should reflect the available
evidence. For example, entering ‘10’ for the 25% reduction
and ‘5’ for the 0% reduction means that the prior belief in
the former is twice as strong as for the latter. Once the
prior distribution is entered, the probabilities of success
and futility and other conditional measures are calculated
and displayed. Varying the prior weights shows how theprobabilities of the various outcomes depend on these
weights. For example, entering zero weight in all but a 25%
reduction gives the overall power of the trial evaluated at
this ‘clinically important difference’, which is 92%.
Owing to more rapid accrual than expected, the actual
NSABP C-08 had only four rather than the planned six
interim analyses [9]. The trial continued to completion,
and the final analysis, conducted in April 2009, showed
that the bevacizumab arm reduced the hazard for DFS
events by 11%. This was not statistically significantly dif-
ferent from control (hazard ratio 0.89, 95% confidence
interval 0.76 to 1.04) P-value = 0.15) [9]. This result was
consistent with our custom prior, which gave the most
weight to a 10 to 15% reduction in hazard.
Discussion
Predicting whether an ongoing clinical trial will be suc-
cessful is of interest to the trial sponsor, the scientific
community, other pharmaceutical companies, and inves-
tors. When the NSABP C-08 trial was initiated, the owner
of bevacizumab was Genentech. As the trial proceeded,
Hoffman-LaRoche was in negotiations to purchase the
50% portion of Genentech stock that it did not already
own. Hoffman-LaRoche became aware of our software as
shown in Figure 4, and they contracted with us to update
the software using the actual accrual from the trial (data
not shown, and not publicly available at the time) rather
than using accrual projected from the protocol.
Figure 2 The symbols use in all panels refer to the prior weights indicated in Figure 1,’ Abbreviations s, simple; p, pessimistic; o,
optimistic; m, moderate; and c, custom. The top five lines and right y-axis show the futility results. The bottom five lines and the left y-axis
show the success results. (A) Predictive probability of success or futility at or before the indicated interim analysis. (B) Probability of success or
futility at the indicated interim analysis conditionally on ‘Continue’ at the previous interim analysis. (C) Predictive probability of eventual success
or futility assuming ‘Continue’ at the previous interim analysis.
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fourth interim analysis. Using their prior probabilities,
they concluded a 55% probability of trial success and
used that prediction to set the price they offered for the
Genentech stock [17]. Genentech determined the prob-
ability of trial success to be 61% [17]. We do not know
the basis of this assessment, but it is close to that of the
moderate prior defined in Figure 1, and it too is substan-
tially less than the trial’s power of 90% claimed in the
protocol (which assumed a 25% reduction in hazard).
We used the NSABP C08 trial as an example to illus-
trate a general approach. Not stopping at an interimFigure 3 Timeline of actual National Surgical Adjuvant Breast and Bo
approximate timing.analysis provides some information about the trial’s pri-
mary endpoint and its eventual success. The amount of
information depends on the trial’s stopping boundaries,
and is usually small. We demonstrated how the informa-
tion gained from the announcement of an interim ana-
lysis that the trial is continuing can be used to make and
update predictions about the final trial conclusion.
NSABP C08 had more planned and actual interim ana-
lyses than is typical in phase III trials. A greater number of
interim analyses provides more opportunity for updating,
but not necessarily more overall interim information. The
number of opportunities for updating may not be thewel Project trial C-08 (NSABP C-08) trial. Asterisk indicates
Figure 4 Screenshot of Excel spreadsheet demonstrating the calculations described in the text. Entry ‘5’ at cell 10B refers to the entry in
cell 7A, and sets the prior probabilities to those labeled ‘Custom’ in row 7. These were the probabilities of the author (DAB) during the early
conduct of National Surgical Adjuvant Breast and Bowel Project trial C-08 (NSABP C-08), and were based on the publicly available information
about bevacizumab and its potential efficacy in treating adjuvant colon cancer, as described in the text. ‘Interim analysis 7’ is actually the final
analysis. The emboldened type in row 18 indicates the probabilities of eventual success, futility, and failure after the fourth interim analysis.
This spreadsheet is available at http://www.berryconsultants.com/wp-content/uploads/2014/02/Unknown-Hazard-Reduction.xls. It allows
users to input their own probabilities, and to experiment with other prior probabilities to see how they affect conclusions. The column
headings are ‘suc’ (the probability of success at the current row’s interim analysis); ‘fut’ (the probability of futility at the current row’s interim
analysis); ‘undec’ (the probability of making no decision at the current row’s interim analysis and continuing the study); ‘suc|undec (the
probability the trial will be declared successful at that row’s interim analysis, given no decision at any previous analysis); ‘fut|undec (the
probability the trial will be declared futile at that row’s interim analysis, given no decision at any previous interim analysis); ‘eventual suc|
undec (the probability the trial will be declared successful at the current, future, or final analysis, given no decision at any previous analysis);
‘eventual fut|undec (the probability the trial will be declared futile at the current, future, or final analysis, given no decision at any previous
analysis); and ‘eventual fail|undec (the probability the trial will fail to show statistical significance given no decision at any previous analysis).
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methodology is the same. Moreover, as regards efficacy,
and assuming that the total amount of type I error allo-
cated to interim analyses is similar, the total amount of in-
formation gleaned from interim analyses is also similar.
The difference for another trial is that the information
may be revealed at a different rate over time.
Trial designs vary more in their approach toward futil-
ity stopping than they do in their approach toward effi-
cacy stopping. The information from an interim analysis
for futility is positive in the sense that not stopping
bodes better for trial success, although the amount of in-
formation may range from minimal to substantial. When
stopping for either efficacy or futility are both possibil-
ities at the same analysis epoch, as in the case of NSABP
C08, then the information that the trial is continuing
could be either positive or negative in relation to ultim-
ate success.
If a trial has no interim analyses, then no updating is
possible. However, even then it is possible to calculate
the predictive probability of trial success using prior in-
formation about treatment effect.
As our example NSABP C08 suggests, the assessment of
prior probabilities of the effect of experimental therapy iscrucial, and prior information is usually more important
than information that accrues from interim analyses.
Assessing prior probabilities is inherently subjective, as we
demonstrated by providing a variety of prior distributions.
In practice, such variety will usually exist, and there may
be even a wider range. In our experience, the worst asses-
sors of prior probabilities tend to be those closest to the
development of the experimental therapy; sometimes they
have been ‘entrapped’ [6]. In our ‘custom’ prior we consid-
ered the performance of bevacizumab in other trials of
colorectal cancer, trials of bevacizumab in other cancers,
trials in cancers involving similar agents, and the sensi-
tivity of colorectal cancer to therapies more generally.
This last point is crucial. It plays the dominant role in
predictions involving diseases such as pancreatic cancer,
glioblastoma multiforme, stroke, sepsis, and Alzheimer’s,
where the overwhelming proportion of phase III trials
have failed.
Having software that quantifies the information con-
tained in announcements of interim analyses raises con-
cerns about ethics and the need to preserve clinical trial
integrity. Our approach does not provide more information,
but rather indicates how to interpret the available informa-
tion. In our experience, interpretations of announcements
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overinterpretations, sometimes in the wrong direction.
This applies to the trials’ investigators and other experts
in the field as well as to venture capitalists and Wall Street
bankers. Having software that provides a more accurate
and usually more tempered interpretation may have a
beneficial and moderating effect.
Although our main focus is on outside observers, soft-
ware that accurately assesses the extent of ‘leakage of infor-
mation’ in a clinical trial’s design may be an aid to clinical
trial designers and trial review bodies. Our software could
help them assess the extent and impact of information
leakage on the trial. No leakage is good, but some leakage
is necessary. The benefits of interim analyses to patients
and to society generally usually greatly outweigh the nega-
tive aspects of information leakage, but assessing the extent
of leakage may lead to a modification of the design that
lessens its potential impact on the trial’s conduct.
In a related vein, modern trialists are introducing adap-
tations that are more complicated than group-sequential
methods [18,19]. If these adaptations become public dur-
ing the trial, and if the trial design is similarly known, then
the observed changes in the trial may convey information
about the relative performance of the treatment arms
[20-22]. Trialists should assess the impact of such know-
ledge outside the sphere of confidentiality of the trial’s
DSMB, and may want to take steps to keep adaptations
confidential or perhaps modify the design.
Conclusions
Announcements of interim analyses for a group-sequential
trial design such as NSABP C-08 reveal that the interim
data lie within a particular range. This information is poten-
tially helpful to clinical trial prognosticators and to clinical
trial designers. Interim analyses such as those in NSABP
C-08 are typically viewed as acceptable with regard to the
amount of information conveyed [18,22]. Not all prognos-
tication is done well, but any prognostication has the po-
tential to influence the course of the trial. Our formal
procedure based on Bayesian updating uses information
that becomes available over time, in order to assess accur-
ately the probability that a clinical trial will be positive.
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